STONY BROOK, NY - Applied DNA Sciences, Inc. (NASDAQ:APDN), a biotechnology firm specializing in PCR-based DNA manufacturing, has announced a collaboration with enzyme producer Alphazyme LLC, to expand the production capacity of a key enzyme used in mRNA therapeutics.
The agreement, revealed today, focuses on scaling up the manufacturing of Applied DNA's proprietary Linea™ RNA polymerase (RNAP), an essential component of the company's Linea™ IVT platform for mRNA production.
The Linea IVT platform is designed to streamline the production of mRNA, offering higher yields and reduced contamination compared to traditional methods. By transitioning from research scale to commercial scale manufacturing, Applied DNA aims to meet increasing demand for its Linea RNAP, coinciding with the company's planned initiation of Good Manufacturing Practice (GMP) capabilities for Linea DNA IVT templates.
Dr. James A. Hayward, president and CEO of Applied DNA, highlighted the importance of commercial-scale Linea RNAP manufacturing for the company's strategy to capitalize on the growing interest in their Linea IVT platform. Alphazyme's expertise in enzyme manufacturing is expected to be instrumental in this scale-up process.
Chad Decker, Vice President and General Manager of Alphazyme, expressed enthusiasm for the partnership, emphasizing their shared goal of advancing high-quality enzyme production to support mRNA manufacturing.
Applied DNA's Linea DNA platform is known for its cell-free DNA production capability, which is scalable and capable of producing a wide range of DNA constructs. The collaboration with Alphazyme is set to enhance the production of Linea RNAP, aligning with Applied DNA's expansion into the nucleic acid-based therapeutics market.
This partnership announcement is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.